1 – 10 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
(
- Contribution to journal › Article
-
Mark
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone 11 Medical and Health Sciences 1103 Clinical Sciences
(
- Contribution to journal › Article
-
Mark
EURO-B.O.S.S. : A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma
(
- Contribution to journal › Article
-
Mark
High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk ewing sarcoma : Results of Euro-E.W.I.N.G.99 and Ewing-2008
(
- Contribution to journal › Article
- 2017
-
Mark
SLUG transcription factor : A pro-survival and prognostic factor in gastrointestinal stromal tumour
(
- Contribution to journal › Article
-
Mark
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib : An exploratory analysis of a randomized clinical trial
(
- Contribution to journal › Article
- 2016
-
Mark
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
(
- Contribution to journal › Article
-
Mark
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
(
- Contribution to journal › Article
-
Mark
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1) : an open-label, international, randomised controlled trial
(
- Contribution to journal › Article
- 2015
-
Mark
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
(
- Contribution to journal › Article